> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# High Court Won’t Hear Boehringer/FTC Case
- URL: https://www.fdaweb.com/high-court-wont-hear-boehringer-ftc-case/
- Published: 2016-01-20T12:00:00.000Z
- Updated: 2026-09-15T02:29:13.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5134482

> The Supreme Court has declined to review a DC Circuit Appeals Court decision in a seven-year antitrust dispute between the Federal Trade Commission (FTC) and Boehringer over questions concerning lawyers’ work-product protections. The *National Law Journal* reports in an online [post](http://www.nationallawjournal.com/id=1202747429246/Justices-Refuse-to-Resolve-Pharmaceutical-Companys-WorkProduct-Battle?mcode=0&curindex=0&curpage=ALL&ref=fdaweb.com) that the company urged the court to hear its claim that the appeals court erred in holding that financial analyses of Boehringer’s patent settlement with Teva’s Barr Pharmaceuticals subsidiary were “fact” work product and not “opinion” work product.  
>  
> Generally, the report says, the “mental impressions, conclusions, opinions, or legal theories of a party’s attorney” are known as opinion work product and are given the greatest protection from discovery during litigation. Work product without a lawyer’s mental impressions or analyses is considered fact work product and is discoverable upon a showing of substantial need, the report says.  
>  
> The appeals court had ruled that financial analyses created at the direction of Boehringer’s in-house counsel in connection with the Barr settlement were fact work product because they were the kind of analyses “anyone familiar with such settlements would expect a competent negotiator to request” and a lawyer’s thoughts related to financial and business decisions were “a matter of business judgment, not legal counsel.”  
>  
> The FTC started its investigation in 2009 after the settlement in which Barr agreed to delay marketing of a generic form of Boehringer’s Aggrenox and in return received $100 million to market the drug to women’s healthcare providers. Boehringer had refused to comply with an FTC subpoena for the financial analyses.